Log in to search using one of your social media accounts:

 

Congress Repeals Medicare Therapy Caps and Lifts Limits on Speech-Generating Devices

Congress has permanently repealed Medicare Part B therapy caps and permanently extended the Steve Gleason Enduring Voices Act, which authorizes the purchase of speech-generating devices (SGDs). The measures were included in a continuing resolution passed yesterday that funds the federal government for the next two years. Medicare Part B Therapy Cap The resolution permanently eliminates the hard cap on how much outpatient speech-language, occupational and physical therapy each Medicare beneficiary is allowed per year. Congress has allowed an exceptions process in most of the past 20 years, but this permanent fix repeals the cap and replaces it with a more flexible targeted medical review threshold of $3,000. Even with a threshold of $3,000, clinicians must use the KX modifier—which indicates ongoing medical necessity—when a patient’s therapy services exceed $2,010 (the level of the previous cap). If an SLP meets certain billing criteria (yet to be announced), the clinician may be required to submit medical records for some of the claims above the $3,000 threshold for review. ASHA anticipates that the targeting criteria and review process will be similar or identical to the most recent therapy caps exceptions process. We will share the details when they become available. Steve Gleason Enduring Voices Act The resolution also requires Medicare to cover the purchase of SGDs permanently. Most of the people who use SGDs have neurodegenerative diseases such as amyot...
Source: American Speech-Language-Hearing Association (ASHA) Press Releases - Category: Speech-Language Pathology Authors: Tags: Advocacy Audiology Speech-Language Pathology Augmentative Alternative Communication Technology Source Type: blogs

Related Links:

In conclusion, the present study demonstrated that TIGIT is a prominent negative immune regulator involved in immunosenescence. This novel finding is highly significant, as targeting TIGIT might be an effective strategy to improve the immune response and decrease age-related comorbidities. Delivery of Extracellular Vesicles as a Potential Basis for Therapies https://www.fightaging.org/archives/2018/01/delivery-of-extracellular-vesicles-as-a-potential-basis-for-therapies/ Here I'll point out a readable open access review paper on the potential use of extracellular vesicles as a basis for therapy: harveste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, we provide an approach to generate OLs in a very rapid and efficient manner, which can be used for disease modeling, drug discovery efforts, and potentially for therapeutic OL transplantation. Graphical abstract Teaser In this article, García-León JA and colleagues demonstrate the generation of functional oligodendrocytes (OLs) from human pluripotent stem cells in a rapid and efficient manner by the single overexpression of SOX10. Generated OLs resemble primary OLs at the transcriptome level and can myelinate neurons both in vivo and in vitro. Neuron-OL co-cultures, adapted to high-th...
Source: Stem Cell Reports - Category: Stem Cells Source Type: research
"Understanding the Role of Hypoxia inducible factor during neurodegeneration for new therapeutics opportunities". Curr Neuropharmacol. 2018 Jan 10;: Authors: Merelli A, Rodriguez JCG, Folch J, Regueiro MR, Camins A, Alberto L Abstract Neurodegeneration (NDG) is linked with the progressive loss of neural function with intellectual and/or motor impairment. Several diseases affecting older individuals, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Huntington's disease, Parkinson's disease, stroke, Multiple Sclerosis and many others, are the most relevant disorders associated wit...
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research
CAMBRIDGE, Mass., Dec. 19, 2017 -- (Healthcare Sales &Marketing Network) -- Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, a central driver of neurological diseas... Biopharmaceuticals, Neurology, Personnel Disarm Therapeutics, SARM1, multiple sclerosis, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Authors: Matilla-Dueñas A, Corral-Juan M, Rodríguez-Palmero Seuma A, Vilas D, Ispierto L, Morais S, Sequeiros J, Alonso I, Volpini V, Serrano-Munuera C, Pintos-Morell G, Álvarez R, Sánchez I Abstract More than 600 human disorders afflict the nervous system. Of these, neurodegenerative diseases are usually characterised by onset in late adulthood, progressive clinical course, and neuronal loss with regional specificity in the central nervous system. They include Alzheimer's disease and other less frequent dementias, brain cancer, degenerative nerve diseases, encephalitis, epilepsy, geneti...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Abstract Pseudobulbar affect (PBA), despite its prevalence and distinctive symptoms, is widely underrecognized and undertreated. It is characterized by uncontrollable laughing or crying that can occur in an exaggerated manner or inappropriately to a given situation or stimuli. PBA is thought to center around preexisting neurological conditions, which include Parkinson disease, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer disease, traumatic brain injury, and stroke. The PBA Registry Series trial was created to measure the prevalence of PBA among patients with these underlying neurological conditions...
Source: The American Journal of Managed Care - Category: Health Management Authors: Tags: Am J Manag Care Source Type: research
Publication date: Available online 22 November 2017 Source:Molecular Aspects of Medicine Author(s): Tommaso Croese, Roberto Furlan Extracellular vesicles (EVs) are released by all neural cells, including neurons, oligodendrocytes, astrocytes, and microglia. The lack of adequate technology has not halted neuroscientists from investigating EVs as a mean to decipher neurodegenerative disorders, still in search of comprehensible pathogenic mechanisms and efficient treatment. EVs are thought to be one of ways neurodegenerative pathologies spread in the brain, but also one of the ways the brain tries to displace toxic proteins,...
Source: Molecular Aspects of Medicine - Category: Molecular Biology Source Type: research
Abstract Starting from 1994, every 2 years, an international workshop is organized focused on calreticulin and other endoplasmic reticulum chaperones. In 2017, the workshop took place at Delphi Greece. Participants from North and South America, Europe, Asia and Australia presented their recent data and discussed them extensively with their colleagues. Presentations dealt with structural aspects of calreticulin and calnexin, the role of Ca(2+) in cellular signalling and in autophagy, the endoplasmic reticulum stress and the unfolded protein response, the role of calreticulin in immune responses. Several presentatio...
Source: J Cell Mol Med - Category: Molecular Biology Authors: Tags: J Cell Mol Med Source Type: research
Abstract Starting from 1994, every 2 years, an international workshop is organized focused on calreticulin and other endoplasmic reticulum chaperones. In 2017, the workshop took place at Delphi Greece. Participants from North and South America, Europe, Asia and Australia presented their recent data and discussed them extensively with their colleagues. Presentations dealt with structural aspects of calreticulin and calnexin, the role of Ca2+ in cellular signalling and in autophagy, the endoplasmic reticulum stress and the unfolded protein response, the role of calreticulin in immune responses. Several presentations focused ...
Source: Journal of Cellular and Molecular Medicine - Category: Molecular Biology Authors: Tags: Review Article Source Type: research
This article is protected by copyright. All rights reserved. PMID: 29159928 [PubMed - as supplied by publisher]
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
More News: ALS | Audiology | Brain | Education | Funding | Government | Graduation | Health Insurance | Health Management | Hospitals | Insurance | Medical Billing | Medicare | Multiple Sclerosis | National Health Service (NHS) | Neurology | Nurses | Nursing | Occupational Health | Pathology | Physical Therapy | Politics | Speech Therapy | Speech-Language Pathology | UK Health | Universities & Medical Training